178 related articles for article (PubMed ID: 36522207)
21. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
22. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Ladenstein R; Pötschger U; Le Deley MC; Whelan J; Paulussen M; Oberlin O; van den Berg H; Dirksen U; Hjorth L; Michon J; Lewis I; Craft A; Jürgens H
J Clin Oncol; 2010 Jul; 28(20):3284-91. PubMed ID: 20547982
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
[TBL] [Abstract][Full Text] [Related]
25. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
van den Berg H; Paulussen M; Le Teuff G; Judson I; Gelderblom H; Dirksen U; Brennan B; Whelan J; Ladenstein RL; Marec-Berard P; Kruseova J; Hjorth L; Kühne T; Brichard B; Wheatley K; Craft A; Juergens H; Gaspar N; Le Deley MC;
Eur J Cancer; 2015 Nov; 51(16):2453-64. PubMed ID: 26271204
[TBL] [Abstract][Full Text] [Related]
26. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
Dirksen U; Brennan B; Le Deley MC; Cozic N; van den Berg H; Bhadri V; Brichard B; Claude L; Craft A; Amler S; Gaspar N; Gelderblom H; Goldsby R; Gorlick R; Grier HE; Guinbretiere JM; Hauser P; Hjorth L; Janeway K; Juergens H; Judson I; Krailo M; Kruseova J; Kuehne T; Ladenstein R; Lervat C; Lessnick SL; Lewis I; Linassier C; Marec-Berard P; Marina N; Morland B; Pacquement H; Paulussen M; Randall RL; Ranft A; Le Teuff G; Wheatley K; Whelan J; Womer R; Oberlin O; Hawkins DS;
J Clin Oncol; 2019 Dec; 37(34):3192-3202. PubMed ID: 31553693
[TBL] [Abstract][Full Text] [Related]
27. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
28. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
[TBL] [Abstract][Full Text] [Related]
29. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04.
Chin M; Yokoyama R; Sumi M; Okita H; Kawai A; Hosono A; Koga Y; Sano H; Watanabe H; Ozaki T; Mugishima H;
Pediatr Blood Cancer; 2020 May; 67(5):e28194. PubMed ID: 32077253
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
DuBois SG; Grier HE
Nat Rev Clin Oncol; 2009 May; 6(5):251-3. PubMed ID: 19390548
[TBL] [Abstract][Full Text] [Related]
31. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
32. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
33. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z
BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278
[TBL] [Abstract][Full Text] [Related]
34. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
DuBois SG; Krailo MD; Glade-Bender J; Buxton A; Laack N; Randall RL; Chen HX; Seibel NL; Boron M; Terezakis S; Hill-Kayser C; Hayes A; Reid JM; Teot L; Rakheja D; Womer R; Arndt C; Lessnick SL; Crompton BD; Kolb EA; Daldrup-Link H; Eutsler E; Reed DR; Janeway KA; Gorlick RG
J Clin Oncol; 2023 Apr; 41(11):2098-2107. PubMed ID: 36669140
[TBL] [Abstract][Full Text] [Related]
35. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
[TBL] [Abstract][Full Text] [Related]
36. Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas.
Bisogno G; Ferrari A; Tagarelli A; Sorbara S; Chiaravalli S; Poli E; Scarzello G; De Corti F; Casanova M; Affinita MC
Pediatr Blood Cancer; 2021 Jul; 68(7):e28951. PubMed ID: 33694265
[TBL] [Abstract][Full Text] [Related]
37. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Paulussen M; Ahrens S; Lehnert M; Taeger D; Hense HW; Wagner A; Dunst J; Harms D; Reiter A; Henze G; Niemeyer C; Göbel U; Kremens B; Fölsch UR; Aulitzky WE; Voûte PA; Zoubek A; Jürgens H
Ann Oncol; 2001 Nov; 12(11):1619-30. PubMed ID: 11822764
[TBL] [Abstract][Full Text] [Related]
38. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
39. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G; De Salvo GL; Bergeron C; Gallego Melcón S; Merks JH; Kelsey A; Martelli H; Minard-Colin V; Orbach D; Glosli H; Chisholm J; Casanova M; Zanetti I; Devalck C; Ben-Arush M; Mudry P; Ferman S; Jenney M; Ferrari A;
Lancet Oncol; 2019 Nov; 20(11):1566-1575. PubMed ID: 31562043
[TBL] [Abstract][Full Text] [Related]
40. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
